Ziyadeh joined Julphar as CEO in February 2023, overseeing 2,000 people. In May 2023, Julphar signed a strategic licensing partnership with China-based Sunshine Lake Pharma, to localize modern insulin analogue manufacturing in MENA. The company reported $240.5 million in revenues for the first half of 2024. Ziyadeh was previously CEO of Tabuk Pharmaceuticals and held leadership positions at Hikma Pharmaceuticals.